URGN
Price:
$10.82
Market Cap:
$456.60M
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The ...[Read more]
Industry
Biotechnology
IPO Date
2017-05-04
Stock Exchange
NASDAQ
Ticker
URGN
According to UroGen Pharma Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 453.60M. This represents a change of -10.04% compared to the average of 504.22M of the last 4 quarters.
The mean historical Enterprise Value of UroGen Pharma Ltd. over the last ten years is 288.44M. The current 453.60M Enterprise Value has changed 15.63% with respect to the historical average. Over the past ten years (40 quarters), URGN's Enterprise Value was at its highest in in the June 2019 quarter at 671.76M. The Enterprise Value was at its lowest in in the December 2015 quarter at 14.19M.
Average
288.44M
Median
268.04M
Minimum
14.22M
Maximum
637.96M
Discovering the peaks and valleys of UroGen Pharma Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 926.88%
Maximum Annual Enterprise Value = 637.96M
Minimum Annual Increase = -54.53%
Minimum Annual Enterprise Value = 14.22M
Year | Enterprise Value | Change |
---|---|---|
2023 | 437.73M | 77.93% |
2022 | 246.01M | 45.95% |
2021 | 168.56M | -41.89% |
2020 | 290.08M | -54.53% |
2019 | 637.96M | 10.55% |
2018 | 577.06M | 70.50% |
2017 | 338.46M | 131.80% |
2016 | 146.01M | 926.88% |
2015 | 14.22M | -49.75% |
2014 | 28.30M | 6.55% |
The current Enterprise Value of UroGen Pharma Ltd. (URGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
284.10M
5-year avg
356.07M
10-year avg
288.44M
UroGen Pharma Ltd.’s Enterprise Value is less than Eliem Therapeutics, Inc. (0), greater than Inhibrx Biosciences, Inc. (15.26M), greater than Merrimack Pharmaceuticals, Inc. (-10189682.00), less than Celcuity Inc. (549.83M), less than Enliven Therapeutics, Inc. (1.03B), greater than Ikena Oncology, Inc. (37.04M), greater than Xilio Therapeutics, Inc. (-2292216.00), greater than Protara Therapeutics, Inc. (130.41M), less than Scholar Rock Holding Corporation (4.26B), greater than Vaccitech plc (-49540805.00), greater than Generation Bio Co. (143.59M), greater than Kronos Bio, Inc. (8.15M), less than Erasca, Inc. (710.66M), greater than C4 Therapeutics, Inc. (280.63M), less than Edgewise Therapeutics, Inc. (2.76B), greater than Ovid Therapeutics Inc. (68.67M), greater than Connect Biopharma Holdings Limited (-54815984.00), greater than PepGen Inc. (108.11M), less than Tyra Biosciences, Inc. (647.39M), greater than Compass Therapeutics, Inc. (176.46M), greater than Vigil Neuroscience, Inc. (34.91M), greater than PureTech Health plc (313.18M),
Company | Enterprise Value | Market cap |
---|---|---|
0 | $342.68M | |
15.26M | $209.76M | |
-10189682.00 | $223.97M | |
549.83M | $465.23M | |
1.03B | $1.13B | |
37.04M | $73.83M | |
-2292216.00 | $50.55M | |
130.41M | $177.43M | |
4.26B | $4.27B | |
-49540805.00 | $192.73M | |
143.59M | $71.47M | |
8.15M | $57.32M | |
710.66M | $726.61M | |
280.63M | $273.18M | |
2.76B | $2.80B | |
68.67M | $68.62M | |
-54815984.00 | $55.03M | |
108.11M | $131.36M | |
647.39M | $744.96M | |
176.46M | $206.38M | |
34.91M | $66.63M | |
313.18M | $476.93M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like UroGen Pharma Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like UroGen Pharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is UroGen Pharma Ltd.'s Enterprise Value?
What is the highest Enterprise Value for UroGen Pharma Ltd. (URGN)?
What is the 3-year average Enterprise Value for UroGen Pharma Ltd. (URGN)?
What is the 5-year average Enterprise Value for UroGen Pharma Ltd. (URGN)?
How does the current Enterprise Value for UroGen Pharma Ltd. (URGN) compare to its historical average?